TF and hyperplasia: The incidence rates of prostatic tumor burdens were markedly decreased, as indicated by reductions in hyperplasia (by 25% at 10 weeks of age, p = 0.033), PIN (by 30% at 12 weeks of age, p = 0.026), primary carcinoma (by 22% at the age of 16 weeks, p = 0.037; by 32% at the age of 20 weeks, p = 0.021; and by 42% at the age of 24 weeks, p = 0.022, respectively), and metastatic disease (by 35% at the age of 24 weeks, p = 0.027; and 38% at the age of 30 weeks, p = 0.019, respectively), in the FABP4−/− TRAMP-HF (TAF) group compared to the TRAMP-HF (TF) group (Figure 2A,B).